• 1
    Harris JR, Lippman ME, Veronesi U, Willett W 1992 Breast cancer. N Engl J Med 327:319328.
  • 2
    Chu KC, Tarone RE, Kessler LG, Ries LAG, Hankey BF, Miller BA, Edwards BK 1996 Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst 88:15711579.
  • 3
    Paterson AHG 1987 Bone metastases in breast cancer, prostate cancer and myeloma. Bone 8:S17S22.
  • 4
    Nielsen OS, Munroe AJ, Tannock IF 1991 Bone metastases: Pathophysiology and management policy. J Clin Oncol 9:509524.
  • 5
    Weiss L 1992 Comments on hematogenous metastasis patterns in human as revealed by autopsy. Clin Exp Metastasis 10:191199.
  • 6
    Coleman RE, Rubens RD 1987 The clinical course of bone metastases from breast cancer. Br J Cancer 55:6166.
  • 7
    Mundy GR, Yoneda T 1995 Facilitation and suppression of bone metastasis. Clin Orthop Rel Res 312:3444.
  • 8
    Fidler IJ 1995 Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 87:15881592.
  • 9
    Powell GJ, Southby J, Danks JA, Stilwell RG, Hayman JA, Henderson MA, Bennett RC, Martin TJ 1991 Localization of parathyroid hormone-related protein in breast cancer metastases: Increased incidence in bone compared with other sites. Cancer Res 51:30593061.
  • 10
    Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massague J, Mundy GR, Guise TA 1999 TGFβ signaling blockade inhibits PTH-rP secretion by breast cancer cells and bone metastases development. J Clin Invest 103:197206.
  • 11
    Carron JA, Fraser WD, Gallagher JA 1997 PTHrP and the PTH/PTHrP receptor are co-expressed in human breast and colon tumours. Br J Cancer 76:10951098.
  • 12
    Zhang Q-X, Borg A, Wolf DM, Oesterreich WS, Fuqua SAW 1997 An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res 57:12441249.
  • 13
    Cailleau RM, Young R, Olive M, Reeves WJ Jr 1974 Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 53:661674.
  • 14
    Yoneda T, Sasaki A, Mundy GR 1994 Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 32:7384.
  • 15
    Yoneda T 1997 Arterial microvascularization and breast cancer colonization in bone. Histol Histopathol 12:11451149.
  • 16
    Yoneda T 1998 Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. Eur J Cancer 34:240245.
  • 17
    Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR 1996 Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98:15441549.
  • 18
    Franzen P, ten Dijke P, Ichijyo H, Yamashita H, Schulz P, Heldin CH, Miyazono K 1993 Cloning of a TGFβ type I receptor that forms a heteromeric complex with the TGFβ type II receptor. Cell 75:681692.
  • 19
    Nishimura R, Moriyama K, Yasukawa K, Mundy GR, Yoneda T 1998 Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells. J Bone Miner Res 13:777785.
  • 20
    Nishimura R, Kato Y, Chen D, Harris SE, Mundy GR, Yoneda T 1998 Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12. J Biol Chem 273:18721879.
  • 21
    Levenson AS, Jordan VC 1997 MCF-7: The first hormone-responsive breast cancer cell line. Cancer Res 57:30713078.
  • 22
    Sasaki A, Boyce BF, Story B, Wright KR, Boyce R, Mundy GR, Yoneda T 1995 Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55:35513557.
  • 23
    Mbalaviele G, Dunstan CR, Sasaki A, Williams PJ, Mundy GR, Yoneda T 1996 E-cadherin expression in human breast cancer cells suppress the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res 56:40634070.
  • 24
    Yoneda T, Sasaki A, Dunstan C, Williams PJ, Bauss F, De Clerck YA 1997 Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 99:25092517.
  • 25
    Jensen FC, Gwatkin RBL, Biggers JD 1964 A simple method which allows simultaneous isolation of specific types of cells. Exp Cell Res 34:440447.
  • 26
    Lagna G, Hata A, Hemmati-Brivanlou A, Massague J 1996 Partnership between DPC4 and SMAD proteins in TGF-beta signaling pathways. Nature 383:832836.
  • 27
    Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE 1996 Growth factors in bone matrix. J Biol Chem 261:1266512674.
  • 28
    Stroschein SL, Wang W, Luo K 1999 Cooperative binding of Smad proteins to two adjacent DNA elements in the plasminogen activator inhibitor-1 promoter mediates transforming growth factor β-induced Smad-dependent transcriptional activation. J Biol Chem 274:94319441.
  • 29
    Christian JL, Nakayama T 1999 Can't get no SMADisfaction: Smad proteins as positive and negative regulators of TGFβ family signals. BioEssays 21:382390.
  • 30
    Imamura T, Takase M, Nishihara A, Oeda E, Hanai J-K, Kawabata M, Miyazono K 1997 Smad6 inhibits signaling by the TGF-β superfamily. Nature 389:622626.
  • 31
    Hata A, Lagana G, Massague J, Hemmati-Brivanlou A 1998 Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev 12:186197.
  • 32
    Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh K, Kawabata M, Heldin N-E, Heldin C-H, ten Dijke P 1997 Identification of Smad7, a TGFβ-inducible antagonist of TGFβ signaling. Nature 389:631635.
  • 33
    Hayashi H, Abdollah S, Qiu YB, Cai JX, Xu YY, Grinnell BW, Richardson MA, Tropper JN, Gimbrone MA Jr, Wrana JL, Falb D 1997 The MAD-related protein Smad7 associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling. Cell 89:11651173.
  • 34
    Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B 1997 The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1332:F105F126.
  • 35
    Rusciano D, Burger MM 1994 Why do cancer cells metastasize into particular organs. BioEssays 14:185193.
  • 36
    Ruoslahti E 1996 How cancer spreads. Sci Am 275:7277.
  • 37
    Adami S 1997 Bisphosphonates and prostate carcinoma. Cancer 80:16681673.
  • 38
    Paget S 1889 The distribution of secondary growths in cancer of the breast. Lancet 1:571573.
  • 39
    Pfeilschifter J, Mundy GR 1987 Modulation of transforming growth factor β activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci USA 84:20242028.
  • 40
    Alevizopoulos A, Mermod N 1997 Transforming growth factor-β: The breaking open of a black box. BioEssays 19:581591.
  • 41
    Kretzscman M, Doody J, Timokhina I, Massague J 1999 A mechanism of repression of TGFβ/Smad signaling by oncogenic Ras. Genes Dev 13:904816.
  • 42
    Luo K, Stroschein SL, Wang W, Chen D, Matens E, Zhou S, Zhou Q 1999 The Ski oncoprotein interacts with the Smad proteins to repress TGFβ signaling. Genes Dev 13:21962206.
  • 43
    Oinchtchouk D, Chen Y-G, Dosch R, Gawantka V, Delius H, Massague J, Niehrs C 1999 Silencing of TGFβ signaling by the pseudoreceptor BAMBI. Nature 401:480484.
  • 44
    Stroschein SL, Wang W, Zhou S, Zhou Q, Luo K 1999 Negative feedback regulation of TGFβ signaling by the SnoN oncoprotein. Science 286:771774.
  • 45
    Massague J, Blain SW, Lo RS 2000 TGFβ signaling in growth control, cancer, and heritable disorders. Cell 103:295309.
  • 46
    Yu H, Rohan T 2000 Role of insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:14721489.
  • 47
    Costantino A, Milazzo G, Giorgino F, Russo P, Goldfine ID, Vigneri R, Belfiore A 1993 Insulin-resistant MDA-MB231 human breast cancer cells contain a tyrosine kinase inhibiting activity. Mol Endocrinol 7:16671676.
  • 48
    Belfiore A, Costantino A, Frasca F, Pandini G, Mineo R, Vigneri P, Maddux B, Goldfine ID, Vigneri R 1996 Overexpression of membrane glycoprotein PC-1 in MDA-MB231 breast cancer cells is associated with inhibition of insulin receptor tyrosine kinase activity. Mol Endocrinol 10:13181326.